Concurrent use of statins and neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis.
Chemoradiotherapy
Colorectal neoplasms
Hydroxymethylglutaryl-CoA reductase inhibitors
Neoadjuvant therapy
Rectal neoplasms
Surgical oncology
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
accepted:
19
08
2021
pubmed:
10
9
2021
medline:
17
11
2021
entrez:
9
9
2021
Statut:
ppublish
Résumé
Statins are used primarily in patients with cardiovascular disease. More recently, they have demonstrated benefit in oncology patients. In vitro models have shown decreased rectal tumor cell viability in cells receiving chemoradiation and statin therapy. In vivo models have been less clear. This study aims to elucidate the impact of concurrent use of statins on the efficacy of neoadjuvant therapy for rectal cancer. Search of Medline, EMBASE, and CENTRAL was performed. Articles were included if they reported complete pathological response (pCR), long-term oncologic outcomes, or chemoradiotherapy-induced toxicity in patients with rectal cancer receiving concurrent statin and neoadjuvant therapy. A pairwise meta-analyses was performed using inverse variance random effects. From 1564 citations, six studies with 726 patients on statin therapy (24.5% female, age: 63.6 years) and 1863 patients not on statin therapy (35.6% female, age: 60.9 years) were included. There was no significant difference in pCR rate between patients on statin therapy and patients not on statin therapy (RR 1.23, 95%CI 0.98-1.54, p = 0.08). Similarly, no difference existed between groups in long-term oncologic outcomes (5-year overall survival: RR 1.03, 95%CI 0.86-1.24, p = 0.75; 5-year disease-free survival: RR 1.04, 95%CI 0.85-1.26, p = 0.73). Chemoradiotherapy-induced toxicities were similar between groups. The concurrent use of statin and neoadjuvant therapy did not significantly impact short- or long-term oncologic outcomes in patients with rectal cancer. Yet, despite pooling of data, this study remained inadequately powered. Larger, prospective studies are required to further elucidate the impact of statins on patients undergoing neoadjuvant therapy for rectal cancer.
Identifiants
pubmed: 34498133
doi: 10.1007/s00384-021-04016-3
pii: 10.1007/s00384-021-04016-3
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2715-2727Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Siegel RL, Miller KD, Fedewa SA et al (2017) Colorectal cancer statistics. CA Cancer J Clin 67(3):177–193. https://doi.org/10.3322/caac.21395
doi: 10.3322/caac.21395
pubmed: 28248415
Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz Gastroenterol 14(2):89–103. https://doi.org/10.5114/pg.2018.81072
doi: 10.5114/pg.2018.81072
pubmed: 31616522
pmcid: 6791134
Griffiths CD, McKechnie T, Lee Y et al (2020) Presentation and survival in colorectal cancer before the age of screening: A systematic review and meta-analysis. Can J Surg
Van Vugt JLA, Reisinger KW, Derikx JPM, Boerma D, Stoot JHMB (2014) Improving the outcomes in oncological colorectal surgery. World J Gastroenterol 20(35):12445–12457. https://doi.org/10.3748/wjg.v20.i35.12445
doi: 10.3748/wjg.v20.i35.12445
pubmed: 25253944
pmcid: 4168077
Iversen LH, Green A, Ingeholm P, Østerlind K, Gögenur I (2016) Improved survival of colorectal cancer in Denmark during 2001–2012: The efforts of several national initiatives. Acta Oncol (Madr) 55:10–23. https://doi.org/10.3109/0284186X.2015.1131331
doi: 10.3109/0284186X.2015.1131331
Fleming F, Pahlman L, Monson JRT (2011) Neoadjuvant therapy in rectal cancer. Dis Colon Rectum 54(7):901–912
doi: 10.1007/DCR.0b013e31820eeb37
Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740. https://doi.org/10.1056/NEJMoa040694
doi: 10.1056/NEJMoa040694
Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U (2005) Swedish rectal cancer trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 23(24):5644–5650. https://doi.org/10.1200/JCO.2005.08.144
doi: 10.1200/JCO.2005.08.144
pubmed: 16110023
Peeters KCMJ, Marijnen CAM, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246(5):693–701. https://doi.org/10.1097/01.sla.0000257358.56863.ce
doi: 10.1097/01.sla.0000257358.56863.ce
pubmed: 17968156
Glynne-Jones R, Hughes R (2012) Critical appraisal of the “wait and see” approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg 99(7):897–909. https://doi.org/10.1002/bjs.8732
doi: 10.1002/bjs.8732
pubmed: 22539154
Habr-Gama A, São Julião GP, Perez RO (2015) Nonoperative management of rectal cancer: Identifying the ideal patients. Hematol Oncol Clin North Am 29(1):135–151. https://doi.org/10.1016/j.hoc.2014.09.004
doi: 10.1016/j.hoc.2014.09.004
pubmed: 25475576
Ryan R, Gibbons D, Hyland JMP et al (2005) Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 47(2):141–146. https://doi.org/10.1111/j.1365-2559.2005.02176.x
doi: 10.1111/j.1365-2559.2005.02176.x
Habr-Gama A, Perez RO, Nadalin W et al (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240(4):711–718. https://doi.org/10.1097/01.sla.0000141194.27992.32
doi: 10.1097/01.sla.0000141194.27992.32
pubmed: 15383798
pmcid: 1356472
Tan Y, Fu D, Li D et al (2019) Predictors and risk factors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer: A poopulation-based analysis. Front Oncol 9:1–9. https://doi.org/10.3389/fonc.2019.00497
doi: 10.3389/fonc.2019.00497
Jonathan Yang T, Goodman KA (2015) Predicting complete response: is there a role for non-operative management of rectal cancer? J Gastrointest Oncol 6(2):241–246. https://doi.org/10.3978/j.issn.2078-6891.2014.110
doi: 10.3978/j.issn.2078-6891.2014.110
pubmed: 25830042
Perreault S, Blais L, Lamarre D et al (2005) Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 59(5):564–573. https://doi.org/10.1111/j.1365-2125.2005.02355.x
doi: 10.1111/j.1365-2125.2005.02355.x
pubmed: 15842555
pmcid: 1884848
Taylor C, Huffman M, Ebrahim S (2013) Statins for primary prevention of cardiovascular disease. JAMA 310(22):2451–2452. https://doi.org/10.1136/bmj.i6334
doi: 10.1136/bmj.i6334
pubmed: 24276813
Shepherd J, Cobbe S, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholestolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 333(20):1301–1307
doi: 10.1056/NEJM199511163332001
Ford ES, Giles WH (2000) Serum C-reactive protein and self-reported stroke. Arter Thromb Vasc Biol 20:1052–1056
doi: 10.1161/01.ATV.20.4.1052
Chan AW, Bhatt DL, Chew DP et al (2002) Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105(6):691–696. https://doi.org/10.1161/hc0602.103586
doi: 10.1161/hc0602.103586
pubmed: 11839623
Hackam DG, Wu F, Li P et al (2011) Statins and renovascular disease in the elderly: a population-based cohort study. Eur Heart J 32(5):598–610. https://doi.org/10.1093/eurheartj/ehq452
doi: 10.1093/eurheartj/ehq452
pubmed: 21156722
Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J Am Med Assoc 279(20):1615–1622. https://doi.org/10.1001/jama.279.20.1615
doi: 10.1001/jama.279.20.1615
Sacks FM, Pfeffer MA, Moye LA et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335(14):1001–1009. https://doi.org/10.1056/NEJM199610033351401
doi: 10.1056/NEJM199610033351401
pubmed: 8801446
Kawata S, Yamasaki E, Nagase T et al (2001) Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84(7):886–891. https://doi.org/10.1054/bjoc.2000.1716
Li Y, He X, Ding Y, Chen H, Sun L (2019) Statin uses and mortality in colorectal cancer patients: an updated systematic review and meta-analysis. Cancer Med 8(6):3305–3313. https://doi.org/10.1002/cam4.2151
doi: 10.1002/cam4.2151
pubmed: 31069997
pmcid: 6558478
Kim WS, Kim MM, Choi HJ et al (2001) Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19(1):81–83. https://doi.org/10.1023/A:1006481423298
doi: 10.1023/A:1006481423298
pubmed: 11291836
Hindler K, Cleeland CS, Rivera E, Collard CD (2006) The role of statins in cancer therapy. Oncologist 11(3):306–315. https://doi.org/10.1634/theoncologist.11-3-306
doi: 10.1634/theoncologist.11-3-306
pubmed: 16549815
Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9:10–19
pubmed: 12538446
Peng J, Lin J, Qiu M et al (2017) Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery. Tumor Biol 39(7). https://doi.org/10.1177/1010428317709638
Bernhard EJ, McKenna WG, Hamilton AD et al (1998) Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 58(8):1754–1761
pubmed: 9563495
Luput L, Sesarman A, Porfire A et al (2020) Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. Cancer Sci 111(4):1344–1356. https://doi.org/10.1111/cas.14312
doi: 10.1111/cas.14312
pubmed: 31960547
pmcid: 7156830
Karagkounis G, DeVecchio J, Ferrandon S, Kalady MF (2018) Simvastatin enhances radiation sensitivity of colorectal cancer cells. Surg Endosc 32(3):1533–1539. https://doi.org/10.1007/s00464-017-5841-1
doi: 10.1007/s00464-017-5841-1
pubmed: 28916945
Katz MS, Minsky BD, Saltz LB, Riedel E, Chessin DB, Guillem JG (2005) Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 62(5):1363–1370. https://doi.org/10.1016/j.ijrobp.2004.12.033
doi: 10.1016/j.ijrobp.2004.12.033
pubmed: 16029794
Hardie C, Jung Y, Jameson M (2016) Effect of statin and aspirin use on toxicity and pathological complete response rate of neo-adjuvant chemoradiation for rectal cancer. Asia Pac J Clin Oncol 12(2):167–173. https://doi.org/10.1111/ajco.12468
doi: 10.1111/ajco.12468
pubmed: 26947944
Armstrong D, Raissouni S, Price Hiller J et al (2015) Predictors of pathologic complete response after neoadjuvant treatment for rectal cancer: a multicenter study. Clin Colorectal Cancer 14(4):291–295. https://doi.org/10.1016/j.clcc.2015.06.001
doi: 10.1016/j.clcc.2015.06.001
pubmed: 26433487
Naseem M, Yeung M, Senthilvel S, Dibajnia P, Naila D, Singh B (2017) Impact of time to surgery in locally advanced rectal cancer patients. J Clin Oncol 35(S4):719–719
doi: 10.1200/JCO.2017.35.4_suppl.719
Mace AG, Gantt GA, Skacel M, Pai R, Hammel JP, Kalady MF (2013) Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum 56(11):1217–1227. https://doi.org/10.1097/DCR.0b013e3182a4b236
doi: 10.1097/DCR.0b013e3182a4b236
pubmed: 24104995
Fransgaard T, Hallas J, Thygesen L, Gogenur I (2019) Association of statin use and oncological outcomes after neoadjuvant radiotherapy in patients with rectal cancer. Anticancer Res 39(4):2177–2182
doi: 10.21873/anticanres.13332
Kotti A, Holmqvist A, Albertsson M, Sun XF (2019) Survival benefit of statins in older patients with rectal cancer: A Swedish population-based cohort study. J Geriatr Oncol 10(5):690–697. https://doi.org/10.1016/j.jgo.2019.01.011
doi: 10.1016/j.jgo.2019.01.011
pubmed: 30692020
Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med 151(4):264–269. https://doi.org/10.1371/journal.pmed.1000097
Stroup D, Berlin J, Morton S et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283(15):2008–2012
doi: 10.1001/jama.283.15.2008
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (Minors): development and validation of a new instrument. ANZ J Surg 73(9):712–716. https://doi.org/10.1046/j.1445-2197.2003.02748.x
doi: 10.1046/j.1445-2197.2003.02748.x
pubmed: 12956787
Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14(1):135. https://doi.org/10.1186/1471-2288-14-135
doi: 10.1186/1471-2288-14-135
pubmed: 4383202
pmcid: 4383202
Lan J (2006) The case of the misleading funnel plot. BMJ 333:597–600
doi: 10.1136/bmj.333.7568.597
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557. https://doi.org/10.1136/bmj.327.7414.557
doi: 10.1136/bmj.327.7414.557
pubmed: 12958120
pmcid: 12958120
Higgins J, Green S (2008) Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, Inc., West Sussex
doi: 10.1002/9780470712184
Pozo ME, Fang SH (2015) Watch and wait approach to rectal cancer: a review. World J Gastrointest Surg 7(11):306–312. https://doi.org/10.4240/wjgs.v7.i11.306
doi: 10.4240/wjgs.v7.i11.306
pubmed: 26649153
pmcid: 4663384
Lorimer PD, Motz BM, Kirks RC et al (2017) Pathologic complete response rates after neoadjuvant treatment in rectal cancer: an analysis of the National Cancer Database. Ann Surg Oncol 24(8):2095–2103. https://doi.org/10.1245/s10434-017-5873-8
doi: 10.1245/s10434-017-5873-8
pubmed: 28534080
Mohiuddin M, Paulus R, Mitchell E et al (2013) Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. Int J Radiat Oncol Biol Phys 86(3):523–528. https://doi.org/10.1016/j.ijrobp.2013.02.020
doi: 10.1016/j.ijrobp.2013.02.020
pubmed: 23545284
pmcid: 4201041
Wong SJ, Moughan J, Meropol NJ et al (2015) Efficacy endpoints of radiation therapy group protocol 0247: A randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 91(1):116–123. https://doi.org/10.1016/j.ijrobp.2014.09.031
doi: 10.1016/j.ijrobp.2014.09.031
pubmed: 25446610
Gérard JP, Azria D, Gourgou-Bourgade S et al (2012) Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30(36):4558–4565. https://doi.org/10.1200/JCO.2012.42.8771
doi: 10.1200/JCO.2012.42.8771
pubmed: 23109696
Glynne-Jones R, Wyrwicz L, Tiret E et al (2017) Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(Supplement 4):iv22-iv40. https://doi.org/10.1093/annonc/mdx224
Monson JRT, Weiser MR, Buie WD, Chang GJ, Rafferty JF (2013) Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum 56(5):535–550. https://doi.org/10.1097/DCR.0b013e31828cb66c
doi: 10.1097/DCR.0b013e31828cb66c
pubmed: 23575392
Petrelli F, Trevisan F, Cabiddu M et al (2020) Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg 271(3):440–448. https://doi.org/10.1097/SLA.0000000000003471
doi: 10.1097/SLA.0000000000003471
pubmed: 31318794
Seymour MT, Morton D (2019) FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol 37(15 (S1))
Zhu S, Brodin NP, English K et al (2019) Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. EClinicalMedicine 16:23–29. https://doi.org/10.1016/j.eclinm.2019.09.009
doi: 10.1016/j.eclinm.2019.09.009
pubmed: 31832617
pmcid: 6890979
Schrag D, Weiser MR, Goodman KA et al (2014) Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 32:513–518
doi: 10.1200/JCO.2013.51.7904
Crane CH, Eng C, Feig BW et al (2010) Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 76(3):824–830. https://doi.org/10.1016/j.ijrobp.2009.02.037
doi: 10.1016/j.ijrobp.2009.02.037
pubmed: 19464823
Rödel C, Liersch T, Becker H et al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13(7):679–687. https://doi.org/10.1016/S1470-2045(12)70187-0
doi: 10.1016/S1470-2045(12)70187-0
pubmed: 22627104
Mach F, Ray KK, Wiklund O et al (2018) Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J 39(27):2526–2539. https://doi.org/10.1093/eurheartj/ehy182
Petrelli F, Sgroi G, Sarti E, Barni S (2016) Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer : a meta-analysis of published studies. Ann Surg 263(3):458–464. https://doi.org/10.1097/SLA.0000000000000368
doi: 10.1097/SLA.0000000000000368
pubmed: 24263329
Du D, Su Z, Wang D, Liu W, Wei Z (2018) Optimal interval to surgery after neoadjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer 17(1):13–24. https://doi.org/10.1016/j.clcc.2017.10.012
doi: 10.1016/j.clcc.2017.10.012
pubmed: 29153429
Dutta SW, Alonso CE, Jones TC, Waddle MR, Janowski EM, Trifiletti DM (2018) Short-course versus long-course neoadjuvant therapy for non-metastatic rectal cancer: patterns of care and outcomes from the National Cancer Database. Clin Colorectal Cancer 17(4):297–306. https://doi.org/10.1016/j.clcc.2018.07.008
doi: 10.1016/j.clcc.2018.07.008
pubmed: 30146228
Erlandsson J, Holm T, Pettersson D et al (2017) Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 18(3):336–346. https://doi.org/10.1016/S1470-2045(17)30086-4
doi: 10.1016/S1470-2045(17)30086-4
Chen K, Xie G, Zhang Q, Shen Y, Zhou T (2018) Comparison of short-course with long-course preoperative neoadjuvant therapy for rectal cancer: a meta-analysis. J Cancer Res Ther 14:S224–S231
doi: 10.4103/0973-1482.202231
Han YD, Kim WR, Park SW et al (2015) Predictors of pathologic complete response in rectal cancer patients undergoing total mesorectal excision after preoperative chemoradiation. Med (United States) 94(45):e1971. https://doi.org/10.1097/MD.0000000000001971
doi: 10.1097/MD.0000000000001971
Peng H, Wang C, Xiao W et al (2018) Analysis of clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. J Cancer 9(15):2687–2692. https://doi.org/10.7150/jca.25493
doi: 10.7150/jca.25493
pubmed: 30087709
pmcid: 6072814